RPS4X and hematologic disorder: In addition, considering that doxorubicin is a key chemotherapeutic agent for several solid and hematological malignancies, our observation that RPS4X suppresses doxorubicin-induced apoptosis implies that RPS4X overexpression may not only promote tumor progression but also contribute to chemotherapeutic resistance.